Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN026 in Refractory Gout
NCT07587684Phase 1Recruiting
- Start
- Jun 2026
- Primary completion
- Aug 2027
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of IN026 in gout (6 arms). Primary endpoint: Incidence of Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs). Started Jun 2026; status: recruiting.
02
Drugs
IN026
03
Conditions
gout
Beyond the preview
Go deeper on NCT07587684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587684.